Oncology drugs

225 results

  • abecma

    (idecabtagene vicleucel)
    Celgene Corporation
    ABECMA is indicated for adult patients with relapsed or refractory multiple myeloma after two or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. It is a BCMA-directed genetically modified autologous T cell immunotherapy.

  • abraxane

    (Paclitaxel)
    Abraxis BioScience, LLC
    ABRAXANE is indicated for treating metastatic breast cancer after chemotherapy failure, as well as for first-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with carboplatin. It is also indicated for first-line treatment of metastatic pancreatic adenocarcinoma combined with gemcitabine.

  • actimmune

    (Interferon gamma-1b)
    Horizon Therapeutics USA, Inc.
    ACTIMMUNE is indicated for reducing serious infections in patients with Chronic Granulomatous Disease (CGD) and for delaying disease progression in severe, malignant osteopetrosis (SMO).

  • adcetris

    (brentuximab vedotin)
    SEAGEN INC.
    ADCETRIS is indicated for treating adult and pediatric patients with previously untreated or relapsed classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), as well as for consolidation post-transplant in high-risk cHL. It is used in combination with specific chemotherapy regimens.

  • adstiladrin

    (nadofaragene firadenovec-vncg)
    Ferring Pharmaceuticals
    ADSTILADRIN® is indicated for treating high-risk BCG-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) in adults, specifically for those with carcinoma in situ (CIS) with or without papillary tumors.

  • afinitor

    (everolimus)
    Novartis Pharmaceuticals Corporation
    AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

  • akynzeo

    (Netupitant and Palonosetron)
    Helsinn Therapeutics (U.S.), Inc.
    AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing cancer chemotherapy, particularly highly emetogenic regimens. It is used in combination with dexamethasone and consists of palonosetron and netupitant (or fosnetupitant in the injection form).

  • alecensa

    (ALECTINIB HYDROCHLORIDE)
    Genentech, Inc.
    ALECENSA is indicated for adjuvant treatment in adults with resected ALK-positive non-small cell lung cancer (NSCLC) and for the treatment of adult patients with metastatic ALK-positive NSCLC, both detected by an FDA-approved test.

  • aliqopa

    (copanlisib)
    Bayer HealthCare Pharmaceuticals Inc.
    ALIQOPA is indicated for adult patients with relapsed follicular lymphoma (FL) who have undergone at least two prior systemic therapies. Its accelerated approval is based on overall response rates, with continued approval dependent on further confirmation of clinical benefit.

  • alunbrig

    (brigatinib)
    Takeda Pharmaceuticals America, Inc.
    ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) confirmed by an FDA-approved test.